Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Pharmacotherapy for hypertension in pregnant patients: special considerations.

Tamargo J, Caballero R, Delpón E.

Expert Opin Pharmacother. 2019 Jun;20(8):963-982. doi: 10.1080/14656566.2019.1594773. Epub 2019 Apr 3. Review.

PMID:
30943045
2.

New drugs in preclinical and early stage clinical development in the treatment of heart failure.

Tamargo J, Caballero R, Delpón E.

Expert Opin Investig Drugs. 2019 Jan;28(1):51-71. doi: 10.1080/13543784.2019.1551357. Epub 2018 Dec 7. Review.

PMID:
30523722
3.

Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels.

Pérez-Hernández M, Matamoros M, Alfayate S, Nieto-Marín P, Utrilla RG, Tinaquero D, de Andrés R, Crespo T, Ponce-Balbuena D, Willis BC, Jiménez-Vazquez EN, Guerrero-Serna G, da Rocha AM, Campbell K, Herron TJ, Díez-Guerra FJ, Tamargo J, Jalife J, Caballero R, Delpón E.

JCI Insight. 2018 Sep 20;3(18). pii: 96291. doi: 10.1172/jci.insight.96291. eCollection 2018 Sep 20.

4.

Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family.

Nieto-Marín P, Jiménez-Jáimez J, Tinaquero D, Alfayate S, Utrilla RG, Rodríguez Vázquez Del Rey MDM, Perin F, Sarquella-Brugada G, Monserrat L, Brugada J, Tercedor L, Tamargo J, Delpón E, Caballero R.

Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):324-332. doi: 10.1016/j.rec.2018.03.012. English, Spanish.

PMID:
29691127
5.

Cardiac Kir2.1 and NaV1.5 Channels Traffic Together to the Sarcolemma to Control Excitability.

Ponce-Balbuena D, Guerrero-Serna G, Valdivia CR, Caballero R, Diez-Guerra FJ, Jiménez-Vázquez EN, Ramírez RJ, Monteiro da Rocha A, Herron TJ, Campbell KF, Willis BC, Alvarado FJ, Zarzoso M, Kaur K, Pérez-Hernández M, Matamoros M, Valdivia HH, Delpón E, Jalife J.

Circ Res. 2018 May 25;122(11):1501-1516. doi: 10.1161/CIRCRESAHA.117.311872. Epub 2018 Mar 7.

6.

Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism.

Subirana I, Fitó M, Diaz O, Vila J, Francés A, Delpon E, Sanchis J, Elosua R, Muñoz-Aguayo D, Dégano IR, Marrugat J.

Sci Rep. 2018 Feb 16;8(1):3191. doi: 10.1038/s41598-018-21482-y.

7.

New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.

Tamargo J, Caballero R, Delpón E.

Cardiovasc Drugs Ther. 2018 Feb;32(1):99-119. doi: 10.1007/s10557-017-6767-5. Review.

PMID:
29372448
8.

Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated than Kir2.1 and Nav1.5 Channels Alone.

Utrilla RG, Nieto-Marín P, Alfayate S, Tinaquero D, Matamoros M, Pérez-Hernández M, Sacristán S, Ondo L, de Andrés R, Díez-Guerra FJ, Tamargo J, Delpón E, Caballero R.

Front Physiol. 2017 Nov 14;8:903. doi: 10.3389/fphys.2017.00903. eCollection 2017.

9.

Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes.

Tamargo J, Rosano GM, Delpón E, Ruilope L, López-Sendón J.

Int J Cardiol. 2017 Apr 15;233:1-11. doi: 10.1016/j.ijcard.2016.11.124. Epub 2016 Nov 9. Review.

PMID:
28161130
10.

Tbx20 controls the expression of the KCNH2 gene and of hERG channels.

Caballero R, Utrilla RG, Amorós I, Matamoros M, Pérez-Hernández M, Tinaquero D, Alfayate S, Nieto-Marín P, Guerrero-Serna G, Liu QH, Ramos-Mondragón R, Ponce-Balbuena D, Herron T, Campbell KF, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Delpón E, Tamargo J.

Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E416-E425. doi: 10.1073/pnas.1612383114. Epub 2017 Jan 3.

11.

Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations.

Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, Gordon LB, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7250-E7259. Epub 2016 Oct 31.

12.

miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation.

Cañón S, Caballero R, Herraiz-Martínez A, Pérez-Hernández M, López B, Atienza F, Jalife J, Hove-Madsen L, Delpón E, Bernad A.

J Mol Cell Cardiol. 2016 Oct;99:162-173. doi: 10.1016/j.yjmcc.2016.08.012. Epub 2016 Aug 18.

PMID:
27545043
13.

Nav1.5 N-terminal domain binding to α1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels.

Matamoros M, Pérez-Hernández M, Guerrero-Serna G, Amorós I, Barana A, Núñez M, Ponce-Balbuena D, Sacristán S, Gómez R, Tamargo J, Caballero R, Jalife J, Delpón E.

Cardiovasc Res. 2016 May 15;110(2):279-90. doi: 10.1093/cvr/cvw009. Epub 2016 Jan 19.

14.

Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L.

Pérez-Hernández M, Matamoros M, Barana A, Amorós I, Gómez R, Núñez M, Sacristán S, Pinto Á, Fernández-Avilés F, Tamargo J, Delpón E, Caballero R.

Cardiovasc Res. 2016 Mar 1;109(3):431-41. doi: 10.1093/cvr/cvv280. Epub 2015 Dec 28.

PMID:
26714926
15.

Cancer chemotherapy and cardiac arrhythmias: a review.

Tamargo J, Caballero R, Delpón E.

Drug Saf. 2015 Feb;38(2):129-52. doi: 10.1007/s40264-014-0258-4. Review.

PMID:
25577497
16.
17.

Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents.

Gómez R, Caballero R, Barana A, Amorós I, De Palm SH, Matamoros M, Núñez M, Pérez-Hernández M, Iriepa I, Tamargo J, Delpón E.

Cardiovasc Res. 2014 Nov 1;104(2):337-46. doi: 10.1093/cvr/cvu203. Epub 2014 Sep 9.

PMID:
25205296
18.

Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current.

Barana A, Matamoros M, Dolz-Gaitón P, Pérez-Hernández M, Amorós I, Núñez M, Sacristán S, Pedraz Á, Pinto Á, Fernández-Avilés F, Tamargo J, Delpón E, Caballero R.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):861-8. doi: 10.1161/CIRCEP.114.001709. Epub 2014 Aug 8.

PMID:
25107449
19.

Functional characterization of a novel frameshift mutation in the C-terminus of the Nav1.5 channel underlying a Brugada syndrome with variable expression in a Spanish family.

Dolz-Gaitón P, Núñez M, Núñez L, Barana A, Amorós I, Matamoros M, Pérez-Hernández M, González de la Fuente M, Alvarez-López M, Macías-Ruiz R, Tercedor-Sánchez L, Jiménez-Jáimez J, Delpón E, Caballero R, Tamargo J.

PLoS One. 2013 Nov 25;8(11):e81493. doi: 10.1371/journal.pone.0081493. eCollection 2013.

20.

Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.

Amorós I, Dolz-Gaitón P, Gómez R, Matamoros M, Barana A, de la Fuente MG, Núñez M, Pérez-Hernández M, Moraleda I, Gálvez E, Iriepa I, Tamargo J, Caballero R, Delpón E.

Biochem Pharmacol. 2013 Jul 15;86(2):267-78. doi: 10.1016/j.bcp.2013.04.023. Epub 2013 May 3.

PMID:
23648307
21.

Drug-induced atrial fibrillation: does it matter?

Tamargo J, Caballero R, Delpón E.

Discov Med. 2012 Nov;14(78):295-9. Review.

22.

p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient.

Núñez L, Barana A, Amorós I, de la Fuente MG, Dolz-Gaitón P, Gómez R, Rodríguez-García I, Mosquera I, Monserrat L, Delpón E, Caballero R, Castro-Beiras A, Tamargo J.

Heart Rhythm. 2013 Feb;10(2):264-72. doi: 10.1016/j.hrthm.2012.10.025. Epub 2012 Oct 18.

PMID:
23085483
23.

Chronic atrial fibrillation up-regulates β1-Adrenoceptors affecting repolarizing currents and action potential duration.

González de la Fuente M, Barana A, Gómez R, Amorós I, Dolz-Gaitón P, Sacristán S, Atienza F, Pita A, Pinto Á, Fernández-Avilés F, Caballero R, Tamargo J, Delpón E.

Cardiovasc Res. 2013 Feb 1;97(2):379-88. doi: 10.1093/cvr/cvs313. Epub 2012 Oct 11.

PMID:
23060133
24.

Drug-induced atrial fibrillation.

Tamargo J, Caballero R, Delpón E.

Expert Opin Drug Saf. 2012 Jul;11(4):615-34. doi: 10.1517/14740338.2012.698609. Review.

PMID:
22724662
25.

New therapeutic targets for the development of positive inotropic agents.

Tamargo J, Duarte J, Caballero R, Delpón E.

Discov Med. 2011 Nov;12(66):381-92. Review.

26.

Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats.

Gómez-Guzmán M, Jiménez R, Sánchez M, Romero M, O'Valle F, Lopez-Sepulveda R, Quintela AM, Galindo P, Zarzuelo MJ, Bailón E, Delpón E, Perez-Vizcaino F, Duarte J.

Br J Nutr. 2011 Nov;106(9):1337-48. doi: 10.1017/S0007114511004314. Epub 2011 Sep 13.

PMID:
21910946
27.

Ranolazine: an antianginal drug with antiarrhythmic properties.

Tamargo J, Caballero R, Delpón E.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27. doi: 10.1586/erc.11.91. Review.

PMID:
21809962
28.

PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis.

Chinchilla A, Daimi H, Lozano-Velasco E, Dominguez JN, Caballero R, Delpón E, Tamargo J, Cinca J, Hove-Madsen L, Aranega AE, Franco D.

Circ Cardiovasc Genet. 2011 Jun;4(3):269-79. doi: 10.1161/CIRCGENETICS.110.958116. Epub 2011 Apr 21.

PMID:
21511879
29.

Dronedarone.

Tamargo J, López-Farré A, Caballero R, Delpón E.

Drugs Today (Barc). 2011 Feb;47(2):109-33. doi: 10.1358/dot.2011.47.2.1545699. Review.

PMID:
21431100
30.

Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome.

Amorós I, Jiménez-Jáimez J, Tercedor L, Barana A, Gómez R, de la Fuente MG, Dolz-Gaitón P, Alvarez M, Martínez-Espín E, Lorente JA, Melgares R, Tamargo J, Delpón E, Caballero R.

Heart Rhythm. 2011 Mar;8(3):463-70. doi: 10.1016/j.hrthm.2010.11.032. Epub 2010 Nov 23.

PMID:
21109023
31.

Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death.

Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpón E, Hu D, Desai M, Borggrefe M, Häissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laiño R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C.

Heart Rhythm. 2010 Dec;7(12):1872-82. doi: 10.1016/j.hrthm.2010.08.026. Epub 2010 Oct 14.

32.

Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.

Tamargo J, Duarte J, Caballero R, Delpón E.

Curr Opin Investig Drugs. 2010 Sep;11(9):1039-47.

PMID:
20730699
33.

Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification.

Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L, Duarte J, López-Izquierdo A, Moraleda I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón E.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15631-6. doi: 10.1073/pnas.1004021107. Epub 2010 Aug 16.

34.

Cardiac electrophysiological effects of nitric oxide.

Tamargo J, Caballero R, Gómez R, Delpón E.

Cardiovasc Res. 2010 Sep 1;87(4):593-600. doi: 10.1093/cvr/cvq214. Epub 2010 Jun 28. Review.

PMID:
20587506
35.

In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both.

Caballero R, de la Fuente MG, Gómez R, Barana A, Amorós I, Dolz-Gaitón P, Osuna L, Almendral J, Atienza F, Fernández-Avilés F, Pita A, Rodríguez-Roda J, Pinto A, Tamargo J, Delpón E.

J Am Coll Cardiol. 2010 May 25;55(21):2346-54. doi: 10.1016/j.jacc.2010.02.028.

36.

Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial fibrillation.

Modrego J, Maroto L, Tamargo J, Azcona L, Mateos-Cáceres P, Segura A, Moreno-Herrero R, Pérez-Castellanos N, Delpón E, Pérez-Villacastín J, Rodríguez E, Macaya C, López-Farré AJ.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):859-68. doi: 10.1111/j.1540-8167.2010.01718.x. Epub 2010 Feb 2.

PMID:
20132404
37.

New investigational drugs for the management of acute heart failure syndromes.

Tamargo J, Amorós I, Barana A, Caballero R, Delpón E.

Curr Med Chem. 2010;17(4):363-90. Review.

PMID:
20015042
38.

Vagal stimulation and atrial electrical remodeling.

Tamargo J, Delpón E.

Rev Esp Cardiol. 2009 Jul;62(7):729-32. No abstract available.

39.

Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.

Barana A, Amorós I, Caballero R, Gómez R, Osuna L, Lillo MP, Blázquez C, Guzmán M, Delpón E, Tamargo J.

Cardiovasc Res. 2010 Jan 1;85(1):56-67. doi: 10.1093/cvr/cvp284.

PMID:
19689982
40.

Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner.

Amorós I, Barana A, Caballero R, Gómez R, Osuna L, Lillo MP, Tamargo J, Delpón E.

J Mol Cell Cardiol. 2010 Jan;48(1):201-10. doi: 10.1016/j.yjmcc.2009.07.011. Epub 2009 Jul 17.

PMID:
19616555
41.

Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels.

Gómez R, Caballero R, Barana A, Amorós I, Calvo E, López JA, Klein H, Vaquero M, Osuna L, Atienza F, Almendral J, Pinto A, Tamargo J, Delpón E.

Circ Res. 2009 Aug 14;105(4):383-92. doi: 10.1161/CIRCRESAHA.109.197558. Epub 2009 Jul 16.

PMID:
19608980
42.

Investigational positive inotropic agents for acute heart failure.

Tamargo J, Caballero R, Gómez R, Barana A, Amorós I, Delpón E.

Cardiovasc Hematol Disord Drug Targets. 2009 Sep;9(3):193-205. Review.

PMID:
19534658
43.

I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.

Tamargo J, Caballero R, Gómez R, Delpón E.

Expert Opin Investig Drugs. 2009 Apr;18(4):399-416. doi: 10.1517/13543780902762850 . Review.

PMID:
19335273
44.

Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome.

Delpón E, Cordeiro JM, Núñez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C.

Circ Arrhythm Electrophysiol. 2008 Aug;1(3):209-18. doi: 10.1161/CIRCEP.107.748103. Erratum in: Circ Arrhythm Electrophysiol. 2008 Aug;1(3):e2. Hofman-Bang, Jacob [added].

45.

Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients.

Sacristán D, Marques M, Zamorano-León JJ, Luque M, Armengol J, Del Castillo J, Martín J, Delpón E, Ramos-Mozo P, de Prada TP, Tamargo J, Barrientos A, Macaya C, López-Farré A.

Proteomics Clin Appl. 2008 Sep;2(9):1300-12. doi: 10.1002/prca.200700021. Epub 2008 Jul 21.

PMID:
21136924
46.

Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1).

Gómez R, Núñez L, Vaquero M, Amorós I, Barana A, de Prada T, Macaya C, Maroto L, Rodríguez E, Caballero R, López-Farré A, Tamargo J, Delpón E.

Cardiovasc Res. 2008 Dec 1;80(3):375-84. doi: 10.1093/cvr/cvn205. Epub 2008 Aug 4.

PMID:
18678642
47.

Effects of MiRP1 and DPP6 beta-subunits on the blockade induced by flecainide of Kv4.3/KChIP2 channels.

Radicke S, Vaquero M, Caballero R, Gómez R, Núñez L, Tamargo J, Ravens U, Wettwer E, Delpón E.

Br J Pharmacol. 2008 Jun;154(4):774-86. doi: 10.1038/bjp.2008.134. Epub 2008 Apr 21.

48.

Effects of atorvastatin and simvastatin on atrial plateau currents.

Vaquero M, Caballero R, Gómez R, Núñez L, Tamargo J, Delpón E.

J Mol Cell Cardiol. 2007 May;42(5):931-45. Epub 2007 Mar 19.

PMID:
17466325
49.

Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy.

Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E.

Pharmacol Ther. 2007 Apr;114(1):107-26. Epub 2006 Dec 29. Review.

PMID:
17287023
50.

Genetically engineered mice as a model for studying cardiac arrhythmias.

Tamargo J, Caballero R, Núñez L, Gómez R, Vaquero M, Delpón E.

Front Biosci. 2007 Jan 1;12:22-38. Review.

PMID:
17127281

Supplemental Content

Loading ...
Support Center